PRostate Olaparib Real World Evidence Study

Official record

Identifier

NCT06031805

Recruiting locations

country

France

Interventions studied

Not provided in the official record

Lead sponsor

AstraZeneca

Target enrolment

159 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Active, not recruiting

First posted

Sep 11, 2023

Last updated on the registry

Sep 28, 2026

Age

18 Years

Sex

MALE

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

* Adult male patients (≥ 18 years old)
* with metastatic castration-resistant prostate cancer,
* who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program
* who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA,

  * Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician);
  * who deceased and who did not object to data collection for research purpose(s) during his or her lifetime.

Exclusion criteria

* Patients opposed to the collection of their data
* Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation

Indexed under

Prostate Cancer